Brief: Lilly's Foundayo Demonstrated Cardiovascular Safety Alongside Sustained A1c Reduction And Weight Loss

Eli Lilly and

30/09/2026 23:29

Oct 1 (Reuters) - Eli Lilly and Company LLY.N:
LILLY'S ORAL GLP-1, FOUNDAYO (ORFORGLIPRON), DEMONSTRATED CARDIOVASCULAR SAFETY ALONGSIDE SUSTAINED A1C REDUCTION AND WEIGHT LOSS IN ITS LARGEST AND LONGEST TYPE 2 DIABETES STUDY
LILLY'S ORAL GLP-1, FOUNDAYO (ORFORGLIPRON), DEMONSTRATED CARDIOVASCULAR SAFETY ALONGSIDE SUSTAINED A1C REDUCTION AND WEIGHT LOSS IN ITS LARGEST AND LONGEST TYPE 2 DIABETES STUDY
ELI LILLY - FOUNDAYO SHOWS 53% LOWER CARDIOVASCULAR DEATH AND 57% LOWER ALL-CAUSE DEATH RISK VERSUS INSULIN GLARGINE
ELI LILLY - FOUNDAYO DEMONSTRATES NON-INFERIOR MACE RISK AND IMPROVED CARDIOMETABOLIC HEALTH VERSUS INSULIN GLARGINE
ELI LILLY - ACHIEVE-4: FOUNDAYO SHOWS 16% LOWER MACE-4 AND 23% LOWER MACE-3 RISK VERSUS INSULIN GLARGINE
ELI LILLY - FOUNDAYO SHOWS SMALLER EGRF REDUCTION AND GREATER ALBUMINURIA REDUCTION VERSUS INSULIN GLARGINE
Source text: ID:nPn3P9w0va
Further company coverage: LLY.N

 ((Reuters.Briefs@thomsonreuters.com;))